Leerink Partnrs Predicts AxoGen FY2029 Earnings

AxoGen, Inc. (NASDAQ:AXGN) – Analysts at Leerink Partnrs issued their FY2029 earnings per share estimates for AxoGen in a research report issued to clients and investors on Tuesday, February 25th. Leerink Partnrs analyst M. Kratky expects that the medical equipment provider will earn $0.38 per share for the year. The consensus estimate for AxoGen’s current full-year earnings is ($0.29) per share.

Separately, Canaccord Genuity Group upped their target price on AxoGen from $22.00 to $26.00 and gave the company a “buy” rating in a research note on Wednesday.

AxoGen Trading Up 3.0 %

AXGN opened at $20.01 on Friday. The stock has a market cap of $880.60 million, a price-to-earnings ratio of -62.53 and a beta of 1.00. The stock’s 50 day moving average price is $17.66 and its 200-day moving average price is $14.99. AxoGen has a one year low of $5.55 and a one year high of $21.00. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.47 and a current ratio of 3.74.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of AXGN. Creative Planning grew its stake in AxoGen by 152.2% in the third quarter. Creative Planning now owns 29,790 shares of the medical equipment provider’s stock worth $418,000 after purchasing an additional 17,980 shares in the last quarter. Sentry Investment Management LLC grew its stake in AxoGen by 9.3% in the third quarter. Sentry Investment Management LLC now owns 17,368 shares of the medical equipment provider’s stock worth $243,000 after purchasing an additional 1,483 shares in the last quarter. Principal Financial Group Inc. bought a new position in AxoGen in the third quarter worth approximately $207,000. Primoris Wealth Advisors LLC bought a new position in AxoGen in the third quarter worth approximately $207,000. Finally, Los Angeles Capital Management LLC bought a new position in AxoGen in the third quarter worth approximately $279,000. Institutional investors own 80.29% of the company’s stock.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.